“Shish kebab” structure provides improved form of “buckypaper”
By American Chemical Society Wednesday, February 8, 2012
ACS Nano
Scientists are reporting development of a new form of buckypaper, which eliminates a major drawback of these sheets of carbon nanotubes — 50,000 times thinner than a human hair, 10 times lighter than steel, but up to 250 times stronger — with potential uses ranging from body armor to next-generation batteries. Their report appears in the journal ACS Nano.
Canada-wide settlement reached in Vioxx class actionsBy Guest Column Thursday, January 19, 2012
LONDON, ON, A settlement has been reached which, if approved by the courts and fully implemented, will resolve Vioxx claims across Canada.
TELUS Health Solutions launches new Canadian health reference portal, myhealthreference.comBy Guest Column Thursday, January 19, 2012
MONTREAL, - TELUS is making access to reliable, verified Canadian healthcare information online a snap with myhealthreference.com. myhealthreference.com, a new health reference internet portal, is designed to help Canadians find the relevant information and tools they need to take better care of their health and the health of their loved ones.
Xarelto® approved as first once-daily, oral anticoagulant for stroke prevention in A FibBy Guest Column Wednesday, January 18, 2012
TORONTO, Bayer Inc. announced today the Health Canada approval of Xarelto® (rivaroxaban tablet) in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate.(1) Xarelto® is the first once-daily oral anticoagulant for this indication that does not require routine coagulation monitoring. Xarelto® is also approved for the prevention of venous thromboembolic events (VTE), or blood clots, in patients who have undergone elective total hip or total knee replacement surgery and has become the number one dispensed anticoagulant prescribed by Canadian orthopedic surgeons in this indication.(2)
Generic Prescription Medicines Saved Canada’s Health-Care System $26-billion Over Past Five YearsBy Guest Column Monday, January 9, 2012
TORONTO, The use of generic prescription medicines has saved Canada’s health-care system nearly $26-billion since 2007, according to an analysis of Canadian retail prescription drug sales information released today by the Canadian Generic Pharmaceutical Association (CGPA).
New ‘solution’ kills hospital superbugs
By News on the Net Thursday, December 29, 2011
By Karin Kloosterman, Israel 21 News
Every patient, nurse, doctor and visitor to a hospital knows the drill: hands get a splash of antibacterial fluid found at every bedside, entrance and exit. Keeping hands clean can prevent some infections, but superbugs—those sometimes deadly bacterial strains resistant to antibiotics—can outwit the best hygiene practices.
New Powerful Painkiller Has Drug Abuse Experts WorriedBy News on the Net Tuesday, December 27, 2011
A Quiz: What’s The Latest Low Carb Product?
By Dr. Gifford Jones Sunday, December 18, 2011
How many readers can answer this question? What kills more North Americans than anything else? I’d bet many would answer heart disease or cancer. Authorities claim heart disease is the number one killer. But I’m convinced that calories are the main culprit killing millions of overweight North Americans. Today, let’s see if the following clues help you name the latest low carb product to combat the high-calorie diet. The answer may surprise you.
Health Canada Approves Abilify®; First Atypical Antipsychotic Treatment for Adoles with SchizBy Guest Column Friday, December 16, 2011
MONTREAL, - Health Canada has approved Abilify® (aripiprazole) for the treatment of schizophrenia in adolescents age 15 to 17, making it the first atypical antipsychotic to be specifically approved for this use in this patient population. Abilify was first approved in 2009 for the treatment of schizophrenia and Bipolar I disorder in adults.
Potential new drugs plug brain’s biological “vacuum cleaner” and target HIVBy Guest Column Wednesday, December 14, 2011
Journal of the American Chemical Society
In an advance toward eliminating pockets of infection in the brain that help make HIV disease incurable, scientists report the development of new substances that first plug the biological vacuum cleaner that prevents anti-HIV drugs from reaching the brain and then revert to an active drug to treat HIV. They describe the advance, which allows medications to cross the so-called “blood-brain barrier” (BBB) and treat brain diseases, in the Journal of the American Chemical Society.
Pre-Diabetes Test For Risk May Hold Key to Prevention - EZSCAN Medical Technology Comes to Canada
By News on the Net Tuesday, November 29, 2011
TORONTO, - Auto Control Medical, a privately owned Toronto-based company that distributes self-monitoring medical devices, is launching EZSCAN in Canada. EZSCAN is a device designed to identify those at risk of developing Type 2 diabetes. This non-invasive testing is painless and takes less than three minutes for the results. “It was developed to identify prediabetes,” said Robert Burgy, President of Auto Control Medical, “if you know you are at risk, then you can do something to try and prevent it from progressing to Type 2 diabetes.”
Visanne®; first oral treatment approved in more than 10 years for Canadian women with endometriBy Guest Column Tuesday, November 29, 2011
TORONTO, - There is now relief for Canadian women living with the pelvic pain associated with endometriosis. The symptoms of endometriosis, including severe menstrual cramps, painful intercourse, painful urination or bowel movements, and lower back or abdominal pain, take a toll on a woman’s emotional health and overall quality of life. Bayer HealthCare announced that Visanne® (2 mg dienogest tablets) was approved by Health Canada for the management of pelvic pain associated with endometriosis. It is the first long-term, oral, progestin-only regimen specifically developed for women with endometriosis in more than 10 years.1
Canadian Patent Issued To Medizone International For AsepticSure™ Disinfection TechnologyBy Guest Column Tuesday, November 29, 2011
San Francisco, CA, Medizone International, Inc. (MZEI:OB) MZEI:QB) reports that the Canadian Patent Office has granted Canadian Patent No 2735739 for processes and systems relating to the platform technology of its revolutionary AsepticSure™ hospital disinfection product.
VICTRELIS™ Now Available for Eligible Patients in OntarioBy Guest Column Tuesday, November 22, 2011
MONTREAL, - Ontarians living with chronic hepatitis C now have publicly funded access to a new treatment option, as Ontario becomes the first province to reimburse VICTRELIS™ (boceprevir). The treatment qualified for a pre-approval rapid review under the Ontario Drug Benefit Act (ODBA), as it successfully met a pre-determined set of criteria, including offering substantial improvements of significant outcomes for the treatment of a serious disease.1
Tuberculosis detector would ferret out disease fasterBy News on the Net Monday, November 7, 2011
Renata d’aliesio, Globe and Mail
Researchers are developing an electronic nose that would sniff out tuberculosis like a Breathalyzer detects alcohol, putting an end to current time-consuming tests and possibly saving hundreds of thousands of lives each year.
Previous 15 Columns Next 15 Columns
